Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team

Introduction

The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories.

Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol.

Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard) and has no regulatory approval for human cancer treatment. Evidence for anticancer effects is primarily preclinical or anecdotal, and clinical trials in humans are lacking.

Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or cancer treatment. There are no completed randomized controlled human clinical trials demonstrating its safety or efficacy against cancer. All human evidence is anecdotal, from case reports, or preclinical (lab/animal) studies. Self-medication carries risks, including liver injury. Always consult an oncologist or integrative physician before considering any off-label or repurposed drug.
Fenbendazole and the Joe Tippens Protocol

What is the Joe Tippens Protocol?

The Joe Tippens Protocol involves fenbendazole, a drug typically used to treat parasitic infections in animals, alongside supplements and lifestyle changes. The protocol aims to disrupt cancer cell growth, though it remains experimental and lacks approval for human use by regulatory bodies like the FDA.

Joe Tippens' Story – Key Facts and Context

  • Diagnosed in 2016 with small-cell lung cancer metastasized to multiple organs; given ~3 months to live.
  • Enrolled in a pembrolizumab (Keytruda) clinical trial at MD Anderson (immunotherapy drug now known to produce durable remissions in some patients).
  • Started fenbendazole (222 mg/day) + supplements after hearing an anecdotal report from a veterinarian about its use in animals.
  • Achieved complete remission by early 2017.
  • Critical confounding factor: He was the only patient in his Keytruda trial cohort to achieve remission, but Keytruda alone can cure a subset of patients with high tumor mutational burden or microsatellite instability.
  • As of 2026, Joe reports scaling back fenbendazole to 3 days/week for prevention and remains in remission.

Lifestyle Recommendations

  • Diet: Eliminate refined sugars and processed foods; focus on whole foods like vegetables, lean proteins, and healthy fats. 
  • Exercise: Engage in regular physical activity, tailored to your health status. 
  • Stress Management: Practice mindfulness, meditation, or other stress-reduction techniques. 
Important Note: Dosing should be guided by a healthcare provider, as fenbendazole and ivermectin are not approved for human cancer treatment, and high doses may pose risks.

Sources: 

Current Versions of the Joe Tippens Protocol (2025)

Original / Classic Joe Tippens Protocol
  • Fenbendazole: 222 mg daily (1 gram packet of Panacur C or Safe-Guard). Take with food/fats for better absorption. Originally 3 days on/4 days off, later switched to daily.
  • Core supplements (Vitamin E was removed in later updates due to interactions):
    • Full-spectrum CBD oil: 25–50 mg/day
    • Curcumin (bioavailable form): 600 mg/day
    • Berberine: 500–600 mg/day (to restrict glucose uptake)
Updated "Onco-Adjunct" Pathways (promoted by Joe Tippens under UltraBotanica branding)
  • Fenbendazole 222 mg (1 gm of Panacur™ or Safeguard™) per day every day. Note if you are using liquid - most liquids are 100 mg/ml. You would take 2.2 ml of the liquid.
  • ONCO ADJUNCT™ Pathway 1™ - 2-4 ml 2 times a day depending on your weight. High-bioavailability CBD + frankincense.
  • ONCO ADJUNCT™ Pathway 2™ - 3 capsules 2 times a day only when you are off chemo. UltraCurcumin + UltraQuercetin + frankincense.
  • ONCO ADJUNCT™ Pathway 3™- With each meal - 1 (one) capsule with a light meal and 2 (two) capsules with a heavy meal if you are trying to starve your cancer of sugars. UltraBerberine (taken with meals to mimic metformin effects).
  • NEW - ONCO ADJUNCT™ Pathway 4™- 2 Capsules twice a day. EGCG + resveratrol + fisetin + beta-glucans
Source: https://mycancerstory.rocks/81-2/ (Last updated: December 2025)
2024–2026 "Turbocharged" Protocols (e.g., Dr. William Makis and community variations)Most modern versions combine fenbendazole with ivermectin and/or mebendazole for purported synergy:
  • Fenbendazole: 222–444 mg daily (up to 1,500 mg/day in aggressive or non-responsive cases), usually 6–7 days/week with 1 day off.
  • Ivermectin: 0.5–1 mg/kg body weight, commonly 24–60 mg flat dose (up to 2 mg/kg in aggressive or non-responsive cases), daily or 5–7 days/week, taken with a high-fat meal.
  • Mebendazole (prescription human alternative): 100–400 mg daily (some reports up to 1,500 mg); often alternated with or used instead of fenbendazole.
  • Bioavailable curcumin: 600–800 mg daily.
  • Berberine: 500–1,000 mg daily.
  • Vitamin D3 + K2: 2,500–5,000 IU daily.
  • Diet and Lifestyle: 
    • A 2026 study (American Association for Cancer Research), linked Ultra-Processed Foods to Reduced Survival after Cancer. Sugar, starch, saturated fat packed into ultra-processed food not only associated with obesity, diabetes, and heart disease, it also worsens cancer prognosis.
    • Another 2026 study published in The BMJ examined how everyday exposure to food preservatives influences cancer risk. The findings were clear — people who consumed more preservatives had higher rates of overall cancer and breast cancer. The findings support recommendations for consumers to favour freshly made, minimally processed foods.
    • Weight loss if overweight (low carb, keto diet, intermittent fasting). A 2026 findings published in Nature Communications, insulin resistance has been linked to a 25% higher risk of 12 different types of cancer. Insulin resistance is often caused by obesity and its associated chronic inflammation. Both diabetes and obesity are associated with a higher risk of cancer. 
    • Adopt a whole-food diet and avoid ultra-processed foods, as recommended by the BMJ 2024 guidelines. 
    • Eliminate sugar consumption as supported by the BMJ 2023 umbrella review, which recommends reducing free and added sugars to below 25 g/day and limiting sugar-sweetened beverages to less than one serving per week to reduce adverse health effects. 
    • Additionally, prioritise adequate sleep and effective stress management to support overall health.
Many users now cycle benzimidazoles (fenbendazole or mebendazole) together with ivermectin.
Sources:

The Science Behind Fenbendazole

Key Scientific Evidence

Other Key Studies

Read More: Fenbendazole cancer success stories (More than 500 case reports)

Joe Tippens’ Story 

In 2016, Joe Tippens was diagnosed with stage 4 small cell lung cancer and given a prognosis of three months. While participating in a clinical trial for Keytruda (pembrolizumab), an FDA-approved immunotherapy, Tippens began the fenbendazole protocol after learning about its potential from a friend. He credits the combination of fenbendazole, supplements, and lifestyle changes with his remission, as his tumors reportedly disappeared within months.

Important Context: Tippens’ participation in the Keytruda trial may have contributed to his outcome, as immunotherapy is effective in some lung cancer cases. The relative contributions of Keytruda and fenbendazole to his recovery are unclear, highlighting the need for controlled studies.

Case Reports and Anecdotal Evidence

Large compilations of anecdotal case reports and testimonials (550+ across cancer types, 2021–2026): https://www.onedaymd.com/2024/02/fenbendazole-cancer-success-stories.html (regularly updated).
Limitations: These cases lack peer-reviewed publication and detailed clinical data (e.g., imaging, concurrent therapies). Some cancers may respond to other treatments or be misdiagnosed as parasitic infections, which fenbendazole could treat. Balanced reporting includes noting that not all patients experience benefits, and outcomes vary widely. 

Risks and Considerations

The Joe Tippens Protocol is experimental, and potential risks include:
  • Side Effects: Fenbendazole may cause liver toxicity or gastrointestinal issues at high doses, though human data is limited [4].
  • Drug Interactions: Curcumin’s antioxidant properties may reduce the efficacy of chemotherapy or radiation, which rely on oxidative stress to kill cancer cells [6].
  • Lack of Regulation: Fenbendazole for human use is not FDA-approved, and sourcing from veterinary suppliers carries risks of contamination or incorrect dosing.
  • Always consult a healthcare provider before starting the protocol, especially if undergoing conventional cancer treatments.

Controversies and Misinformation

The protocol’s popularity surged after Tippens’ story went viral, leading to widespread interest and some misinformation:
  • 2020 South Korea Fenbendazole Scandal: Misleading claims about fenbendazole’s efficacy led to overuse, with some patients abandoning conventional treatments.
  • Misdiagnosis Hypothesis: Some speculate that cancers responsive to fenbendazole may be parasitic infections misdiagnosed as cancer. However, Tippens’ diagnosis was confirmed via biopsy, making this unlikely in his case.
  • Anecdotal vs. Scientific Evidence: The protocol’s reliance on personal stories rather than large-scale trials has fueled debate about its validity.
  • Readers should approach claims critically and seek information from reputable sources like the National Cancer Institute (NCI) or peer-reviewed journals.

Next Steps

If you’re considering the Joe Tippens Protocol:
  • Consult a Healthcare Provider: Discuss the protocol’s risks and benefits with an oncologist or integrative medicine specialist.
  • Stay Informed: Visit reputable resources like the NCI (cancer.gov) or Independent Medical Alliance, formerly FLCCC (imahealth.org) for updates on fenbendazole research.
  • Join Support Groups: Engage with verified communities, such as those on X or cancer forums, to learn from others’ experiences while verifying information.
Recommendations (2026 Perspective)
  1. Never abandon conventional oncology care — fenbendazole is at best an adjunct.
  2. If you choose to explore it despite the lack of evidence:
    • Use only pharmaceutical-grade product (Lab-tested pure powder).
    • Start at the standard 222 mg/day and increase only if tolerated.
    • Always take with dietary fat for absorption.
    • Consider prescription mebendazole instead (better human safety data).
  3. Most promising adjuncts based on mechanistic and anecdotal synergy: ivermectin, berberine, bioavailable curcumin, ketogenic diet, avoid processed foods.
  4. Await proper trials — several mebendazole and ivermectin studies are actively recruiting; fenbendazole pilot studies are being planned but none are active yet.

Conclusion

The Joe Tippens Protocol offers hope to some cancer patients, but its evidence is primarily anecdotal and preclinical. While Joe Tippens’ story and case reports are compelling, the protocol’s effectiveness remains unproven without large-scale clinical trials. Potential risks, such as drug interactions and lack of regulation, underscore the need for medical supervision. By combining curiosity with caution, readers can explore this experimental approach responsibly while prioritizing evidence-based care.

As of February 2026, fenbendazole cannot be recommended as a proven or standard cancer treatment by most conventional oncologists. The expanding body of case reports and strong mechanistic rationale justify urgent clinical trials, but until those results are available, any use should be cautious, closely monitored, and never in lieu of evidence-based therapy. Stay informed, stay skeptical, and always work hand-in-hand with your medical team.

Frequently Asked Questions (FAQs)

  • Is fenbendazole safe for human use?
    • Fenbendazole is not approved for human cancer treatment. Limited studies suggest it’s well-tolerated at specific doses, but long-term safety is unknown. Consult a doctor before use.
  • Can I combine the protocol with chemotherapy?
    • Some components (e.g., curcumin) may interfere with chemotherapy. Discuss with your oncologist to avoid interactions.
  • Where can I source fenbendazole?
    • Veterinary products like Panacur C are commonly used, but sourcing for human use is unregulated. Ensure purity and consult a healthcare provider.
  • Are there clinical trials for fenbendazole?
    • As of 2026, fenbendazole clinical trials in oncology are limited; related drugs like mebendazole are being studied more actively. Check databases like ClinicalTrials.gov for updates.

Disclaimer: This article is for educational purposes only and is not medical advice. Fenbendazole and the Joe Tippens Protocol are not approved for cancer treatment by FDA, EMA, or other regulatory authorities. Always consult an oncologist or qualified healthcare professional before considering any off-label, repurposed, or experimental therapies






Ivermectin and mebendazole, both approved for human use, are now available in the U.S.

Researched and approved by Dr. Peter McCullough.
  • Prescribed by licensed medical professionals
  • Compounded and dispensed by a licensed US-based pharmacy
  • Approved for human use
Where to buy Ivermectin and Mebendazole Formula: Available on The Wellness Company's website. Here is the link: Ivermectin and Mebendazole.

Comments

  1. Kathryn KellyOctober 12, 2025 at 9:49 AM

    IVM and fenbendazole are winners in cancer treatment, as my husband can testify. Unfortunately there is someone on X impersonating Joe Tippens, whose real Facebook account says is the only social media account he has. They are using Tippens' name to con people out of hundreds of dollars for IVM and fenbendazole, scamming the sick and the elderly. I have tried to report him to X but can't get through their AI wall. So be careful and DO NOT order from the grifter on X!

    ReplyDelete

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2025 Edition)

By Editorial Team
Image
Ivermectin, a drug primarily used to treat parasitic infections, has gained attention for its potential anti-cancer properties, particularly in alternative treatment protocols. Popularized by figures like Dr. William Makis, these protocols combine ivermectin with supplements and lifestyle changes to target aggressive cancers. This article explores the science, protocols, case reports, risks, and controversies surrounding ivermectin’s use in cancer treatment, providing a balanced guide for readers. What is the Ivermectin Cancer Protocol? Ivermectin cancer protocols, notably those developed by Dr. William Makis, combine ivermectin with supplements like curcumin, vitamin D, and berberine, alongside dietary and lifestyle changes. These protocols are tailored to cancer severity, with higher doses recommended for aggressive cases. The term “turbo cancers,” used by some proponents, refers to rapidly progressing cancers, though it is not a standard medical term and lacks clear scientific defin...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 360 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2025)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Best Fenbendazole Dosage for Cancer in Humans: Benefits, Risks, and Guidelines (2025)

By Editorial Team
Image
What is Fenbendazole? Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discover...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146  (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balstilimab in patients wit...
Read more